Combined cryotherapy and external beam radiation therapy for the treatment of intermediate-risk localized prostate cancer: A case series


Introduction: Routine PSA screening for prostate cancer (PCa) has increased the detection of intermediate-risk, localized disease. Conventional treatments for localized PCa include surgery, brachytherapy, cryotherapy or external beam radiotherapy (EBRT). However, for intermediate risk patients, rates of recurrence are moderately high and a multi-modal treatment approach for these patients may be necessary. We treated patients with a combination of cryotherapy and low dose EBRT to assess the safety and feasibility of this combinatory approach as well as to evaluate early oncological outcomes. Case Presentation: Men with intermediate risk (PSA = 10-20 ng/ml and/or Gleason = 7 and/or clinical T2b) localized PCa were prospectively enrolled in this study. Patients underwent cryotherapy and then 39 Gy EBRT 4-6 weeks after surgery. After completing EBRT, the men were followed every 3 months for 2 years. Adverse events, PSA, urinary and erectile function were assessed during each follow-up. Three patients completed the study. Preoperative PSA ranged from 3.5 to 7.9 ng/ml. There were no intraoperative complications and the treatment was well tolerated. Following cryotherapy and EBRT, all patients were pad-free within 6 months and remained continent for the duration of the study. Bother index remained stable throughout the study for all patients. No urethral strictures or rectal toxicities were observed. PSA remained undetectable for all patients. Conclusions: In this prospective study, cryotherapy combined with low dose EBRT was a safe approach for the treatment of intermediate-risk, localized PCa. Early oncological outcomes appeared to be favorable with all patients having undetectable PSA during the 2-year follow-up period. Further studies are warranted to confirm these preliminary results.

Share and Cite:

Qi, P. , Tsivian, M. , Vujaskovic, Z. and Polascik, T. (2014) Combined cryotherapy and external beam radiation therapy for the treatment of intermediate-risk localized prostate cancer: A case series. Case Reports in Clinical Medicine, 3, 47-51. doi: 10.4236/crcm.2014.31012.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Littrup, P.J. (1997) Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society. Cancer, 80, 1864-1870.<1864::AID-CNCR27>3.0.CO;2-2
[2] D’Amico, A.V., Whittington, R., Malkowicz, S.B., et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. The Journal of the American Medical Association, 280, 969-974.
[3] Nag, S., Beyer, D., Friedland, J., Grimm, P. and Nath, R. (1999) American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. International Journal of Radiation Oncology*Biology*Physics, 44, 789-799.
[4] Tewari, A. (2003) Management of clinically localized prostate cancer: Pathologic processing to robotic prostatectomy. Reviews in Urology, 5, S33-S39.
[5] Sharkey, J., Cantor, A., Solc, Z., et al. (2002) Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Current Urology Reports, 3, 250-257.
[6] Quaranta, B.P., Marks, L.B. and Anscher, M.S. (2004) Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology (Williston Park), 18, 1289-1302; Discussion 302-304, 309.
[7] Kupelian, P.A., Elshaikh, M., Reddy, C.A., Zippe, C. and Klein, E.A. (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostatespecific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. Journal of Clinical Oncology, 20, 3376-3385.
[8] Vicini, F.A., Martinez, A., Hanks, G., et al. (2002) An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer, 95, 2126-2135.
[9] Thompson, I., Thrasher, J.B., Aus, G., et al. (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. Journal of Urology, 177, 2106-2131.
[10] Caso, J.R., Tsivian, M., Mouraviev, V., Kimura, M. and Polascik, T.J. (2011) Complications and postoperative events after cryosurgery for prostate cancer. BJU International, 109, 840-845.
[11] Donnelly, B.J., Saliken, J.C., Ernst, D.S., et al. (2002) Prospective trial of cryosurgical ablation of the prostate: Five-year results. Urology, 60, 645-649.
[12] Robinson, J.W., Donnelly, B.J., Saliken, J.C., Weber, B.A., Ernst, S. and Rewcastle, J.C. (2002) Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology, 60, 12-18.
[13] Han, K.R., Cohen, J.K., Miller, R.J., et al. (2003) Treatment of organ confined prostate cancer with third generation cryosurgery: Preliminary multicenter experience. Journal of Urology, 170, 1126-1130.
[14] Polascik, T.J., Nosnik, I., Mayes, J.M. and Mouraviev, V. (2007) Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology, 70, 117-121.
[15] Babaian, R.J., Donnelly, B., Bahn, D., et al. (1993) Best practice statement on cryosurgery for the treatment of localized prostate cancer. Journal of Urology, 180, 1993-2004.
[16] Ahmed, S. and Davies, J. (2005) Managing the complications of prostate cryosurgery. BJU International, 95, 480-481.
[17] Han, K.R. and Belldegrun, A.S. (2004) Third-generation cryosurgery for primary and recurrent prostate cancer. BJU International, 93, 14-18.
[18] Shinohara, K., Rhee, B., Presti Jr., J.C. and Carroll, P.R. (1997) Cryosurgical ablation of prostate cancer: Patterns of cancer recurrence. Journal of Urology, 158, 2206-2209; Discussion 9-10.
[19] Bolla, M., Collette, L., Blank, L., et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet, 360, 103-106.
[20] Leibovich, B.C., Engen, D.E., Patterson, D.E., et al. (2000) Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. Journal of Urology, 163, 1178-1182.
[21] Carson 3rd, C.C., Zincke, H., Utz, D.C., Cupps, R.E. and Farrow, G.M. (1980) Radical prostatectomy after radio-therapy for prostatic cancer. Journal of Urology, 124, 237-239.
[22] Anscher, M.S., Robertson, C.N. and Prosnitz, R. (1995) Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: Ten-year update. International Journal of Radiation Oncology*Biology*Physics, 33, 37-43.
[23] Odrazka, K., Dolezel, M., Vanasek, J., et al. (2010) Time course of late rectal toxicity after radiation therapy for prostate cancer. Prostate Cancer and Prostatic Diseases, 13, 138-143.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.